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Supplementary Table 1.  Study population in detail based on initial randomization to different 
intervention groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Included in this analysis (n=861 i.e. 427 + 434) Excluded from this analysis 
 
                      Aspirin  
 
            Aspirin Placebo (AP)  
 
Randomised to Resistant Starch (RS) 
or Resistant Starch Placebo (RSP) 
only  
 
 Aspirin and RS    214 RS and AP 
 
208    RS only 41 
 Aspirin and RSP 
 
  204 RSP and AP 
 
216 
  
RSP only 
 
35 
 
 Aspirin only 
 
      9 AP only   10   
Total  (937)  
 
  427  434  76 
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Supplementary Table 2: The distribution of Serious Adverse Events by randomization group to aspirin 
intervention on intervention phase 
 
 
Supplementary table 2 continued: Detailed breakdown of  Serious Adverse Events 
 
 Aspirin  
N (427) 
AP  
N (434) 
   
Probable or possible peptic ulcer 7 8 
Cerebrovascular events 2 1 
Cardiovascular events 1 5 
Deep Venous thrombosis 2 0 
Major other 4 9 
Minor Other including bleeding 5 1 
TOTALS 21 24 
   
Abdominal abcess 0 0 
Acute cholecystectitis 1 1 
Anaemia 1 0 
Anal epithelioma 0 1 
Aspergillosis 1 0 
Atrial fibrillation 0 0 
Black stools 1 1 
Bladder stone 0 1 
Bleeding from femoral artery 1 0 
Breast cancer 1 2 
Caecal spirochaetosis 0 0 
Cardiac pain 0 1 
Cellulitis in leg 0 0 
Cerebral haemorrhage 0 0 
Cerebral vasculitis 0 1 
Coronary arterial stenosis 0 1 
Coronary thrombosis 1 0 
Died (before receiving therapy) 0 0 
Duodenal ulcers 3 3 
Deep venous thrombosis 2 0 
Endophlebitis 0 0 
Failure of anal stoma repair to heal 0 1 
Gastric ulcer 0 1 
Gastritis 0 1 
Gastrointestinal bleed 1 1 
Gum bleeding 1 0 
Hernia with gastric reflux 0 0 
Hip replacement 0 1 
Liver cancer 1 0 
Lung sarcoidosis 0 1 
Malignant melanoma 1 0 
Meningioma brain tumour 0 1 
Myocardial infarction 0 2 
Numbness on one side of body 0 1 
Operation to close abdominal jejunostomy 0 1 
Pancreatic cyst 0 1 
Hysterectomy 0 1 
Pre-tracheal lymphoma 0 1 
Prostate cancer 1 0 
Pyelonephritis 0 0 
Rectal bleed 1 1 
Severe nose bleed 1 0 
Spinal canal stenosis 0 1 
Stroke 2 0 
Testicular mass 0 1 
Vaginal bleeding 1 0 
Ventricular fibrillation 0 1 
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Supplementary Table 3.  Demographic details for those with follow-up information showing time on study in months 
 
 Participants with further long-term 
follow up data 
Participants without long-term follow 
up data 
Total  
Number of participants 671 190 861 
Time on CAPP2 intervention study mean  (sd) (range)  
0-23 months  
24-47 months 
48+ months 
27·0 (13·0) (1·1, 74·4) 
186 (27·7%) 
395 (58·9%) 
90 (13·4%) 
 
18·6 (12·9) (0·8, 60·6) 
115 (60·6%) 
66 (34·7%) 
9 (4·7%) 
25.2 (13·4) (0·8,74·4) 
301 (35·0%) 
461 (53·5%) 
99 (11·5%) 
Time since study entry mean (sd) (range) 
0-23 months 
24-47 months 
48-59 months 
60+ months 
66·1 (26·8) (2·5, 128) 
28 (4·2%) 
123 (18·3%) 
126 (18·8%) 
394 (58·7%) 
18·6 (12·9) (0·8, 60·6) 
117 (61·6%) 
64 (33·7%) 
8 (4·2%) 
1 (0·5%) 
55·7 (31·4) (0·8,128) 
145 (16·8%) 
187 (21·7%) 
134 (15·6%) 
395 (45·9%) 
Age at recruitment mean (sd) (range) 
21-36 years 
37-45 years 
46-53 years 
54- 78 years 
 
44·7 (10·6) (24·7, 75·5) 
159 (23·7%) 
166 (24·8%) 
170 (25·3%) 
176 (26·2%) 
 
43·0 (10·7) (21·5, 77·9) 
56 (29·5%) 
49 (25·8%) 
45 (23·7%) 
40 (21·0%) 
44·3 (10·6) (21·5,77·9) 
215 (25%) 
215 (25%) 
215 (25%) 
216 (25%) 
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Supplementary Table 4.   Number of years until first colorectal cancer diagnoses by years since 
randomization for those with a CRC diagnosis 
 
 
* This group was not included in the analysis for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Years Since 
randomization  
Randomized to aspirin  
(N=427) 
Randomized to AP (N=434) Randomized to RS or RSP 
only (N=76)*
0-1 1 0 0 
1-2 5 6 0 
2-3 5 7 2 
3-4 1 1 2 
4-5 2 3 1 
5-6 1 4 2 
6-7 1 2 0 
7-8 1 4 0 
8-9 1 1 0 
9-10 0 0 0 
10-11 0 2 0 
Total  18 30 7 
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Supplementary Table 5.  Distribution of Lynch Syndrome related cancers 
 
 Randomized to 
aspirin  (N=427) 
Randomized to AP 
(N=434) 
Randomized to RS or 
RSP only (N=76)* 
Total 
Participants with cancer attributed to 
Lynch Syndrome 
    
Colorectal cancer 
 
18 30 7 55 
Other Lynch Syndrome cancers: 
- Endometrial  
- Pancreas 
- Ureter 
- Brain 
- Small Bowel 
- Gastric 
- Cholangiocarcinoma 
- Kidney 
- Ovarian 
16 
 
5 
3 
2 
2 
0 
0 
1 
0 
3 
22 
 
13 
2 
1 
0 
2 
2 
0 
1 
1 
4 
 
3 
0 
0 
0 
1 
0 
0 
0 
0 
42 
 
21 
5 
3 
2 
3 
2 
1 
1 
4 
 
TOTAL 
 
34 
 
52 
 
11 
 
97 
 
* This group was not included in the analysis for this study.  
6 
Supplementary figure 1. Kaplan-Meier function of time to first non-CRC Lynch syndrome cancer 
comparing those randomized to aspirin with those randomized to aspirin placebo (AP) adjusted for 
gender. Each point on the plot shows the estimated cumulative incidence by years of follow-up together 
with the corresponding 95% confidence interval. 
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Supplementary Table 6 CRC by participants’ molecular diagnosis 
 
Gene Status 
 
CRC not detected 
N(%) 
CRC diagnoses* 
N(%) 
Total 
Clinical diagnosis 
 
156 (96) 7 (4) 163  
MSH2 mutation carrier 
 
264 (93) 20 (7) 284 
MLH1 mutation carrier 
 
436 (94) 28 (6) 464 
MSH6 mutation carrier 
 
26 (100) 0 (0) 26 
Total 
 
883 (94) 55 (6) 937 
 
*Includes 7 cases with CRC randomized to RS or RSP only 
